Negative effects of melatonin on depression

Carman, JohnScott; Post, Robert M.; Buswell, R; Goodwin, FK

doi:10.1176/ajp.133.10.1181

Cited by 141 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding evidence assessing melatonin for BD, one open-label study showed no significant effects on mood or sleep in rapid-cycling patients ( 351 ), whereas in another small open-label study it showed sleep-enhancing and antimanic effects in manic patients ( 352 ). As mentioned previously, agomelatine, an agonist of melatonin MT1 and MT2 receptors, has demonstrated preliminary evidence of efficacy in bipolar depression ( 353 ), but agomelatine has other actions on the serotonin system.…”

Section: Effects Of Pharmacotherapy On Mitochondrial Functionsmentioning

confidence: 99%

The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment

et al. 2021

View full text Add to dashboard Cite

Mitochondria are cellular organelles involved in several biological processes, especially in energy production. Several studies have found a relationship between mitochondrial dysfunction and mood disorders, such as major depressive disorder and bipolar disorder. Impairments in energy production are found in these disorders together with higher levels of oxidative stress. Recently, many agents capable of enhancing antioxidant defenses or mitochondrial functioning have been studied for the treatment of mood disorders as adjuvant therapy to current pharmacological treatments. A better knowledge of mitochondrial physiology and pathophysiology might allow the identification of new therapeutic targets and the development and study of novel effective therapies to treat these specific mitochondrial impairments. This could be especially beneficial for treatment-resistant patients. In this article, we provide a focused narrative review of the currently available evidence supporting the involvement of mitochondrial dysfunction in mood disorders, the effects of current therapies on mitochondrial functions, and novel targeted therapies acting on mitochondrial pathways that might be useful for the treatment of mood disorders.

show abstract

Section: Effects Of Pharmacotherapy On Mitochondrial Functionsmentioning

confidence: 99%

The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although melatonin is the hormone of the pineal gland, MTNR1A is ubiquitously expressed, predominantly in the suprachiasmatic nucleus, hypothalamus and prefrontal cortex. The melatonin receptor pathway is known to be involved in depression (Carman et al 1976; Wetterberg et al 1984; Goldstein, 1985; Bourin & Prica, 2009; Anderson, 2010; Gałecka et al 2011) and its relationship with somatic complaints, and vitality in general, makes it a biologically plausible gene.…”

Section: Discussionmentioning

confidence: 99%

Somatic, positive and negative domains of the Center for Epidemiological Studies Depression (CES-D) scale: a meta-analysis of genome-wide association studies

Demirkan¹,

Lahti²,

Direk³

et al. 2016

Psychol. Med.

View full text Add to dashboard Cite

Background Major depressive disorder (MDD) is moderately heritable, however genome-wide association studies (GWAS) for MDD, as well as for related continuous outcomes, have not shown consistent results. Attempts to elucidate the genetic basis of MDD may be hindered by heterogeneity in diagnosis. The Center for Epidemiological Studies Depression (CES-D) scale provides a widely used tool for measuring depressive symptoms clustered in four different domains which can be combined together into a total score but also can be analysed as separate symptom domains. Method We performed a meta-analysis of GWAS of the CES-D symptom clusters. We recruited 12 cohorts with the 20-or 10-item CES-D scale (32 528 persons). Results One single nucleotide polymorphism (SNP), rs713224, located near the brain-expressed melatonin receptor (MTNR1A) gene, was associated with the somatic complaints domain of depression symptoms, with borderline genome-wide significance (pdiscovery = 3.82 × 10−8). The SNP was analysed in an additional five cohorts comprising the replication sample (6813 persons). However, the association was not consistent among the replication sample (pdiscovery +replication = 1.10 × 10−6) with evidence of heterogeneity. Conclusions Despite the effort to harmonize the phenotypes across cohorts and participants, our study is still underpowered to detect consistent association for depression, even by means of symptom classification. On the contrary, the SNP-based heritability and co-heritability estimation results suggest that a very minor part of the variation could be captured by GWAS, explaining the reason of sparse findings.

show abstract

“…Melatonin injections given in the morning stimulate tumour growth, whereas same doses given in the mid-afternoon have no effect but in the evening have a retarding effect [72, 73]. Melatonin administration may unduly prolong the nocturnal melatonin rise or that is given throughout the day may exacerbate bipolar and classic depression [74, 75]. Some people with depression may suffer from a low-melatonin syndrome [76].…”

Section: Negative Effects Of Melatoninmentioning

confidence: 99%

Melatonin: A Novel Indolamine in Oral Health and Disease

Chava

Sirisha

2012

International Journal of Dentistry

View full text Add to dashboard Cite

This paper attempts to summarise the findings accumulated within the last few years concerning the hormone of darkness “melatonin.” Based on its origin, from the pineal gland until recently it was portrayed exclusively as a hormone. Due to its lipophilic nature, it is accessible to every cell. Thus, in the classic sense it is a cell protector rather than a hormone. Recent studies, by Claustrat et al. (2005), detected few extrapineal sources of melatonin like retina, gastrointestinal tract, and salivary glands. Due to these sources, research by Cutando et al. (2007), is trying to explore the implications of melatonin in the oral cavity, in addition to its physiologic anti-oxidant, immunomodulatory and oncostatic functions at systemic level that may be receptor dependent or independent. Recently, certain in vivo studies by Shimozuma et al. (2011), detected the secretion of melatonin from salivary glands further emphasising its local activity. Thus, within our confines the effects of melatonin in the mouth are reviewed, adding a note on therapeutic potentials of melatonin both systemically and orally.

show abstract

Negative effects of melatonin on depression

Cited by 141 publications

References 38 publications

The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment

The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment

Somatic, positive and negative domains of the Center for Epidemiological Studies Depression (CES-D) scale: a meta-analysis of genome-wide association studies

Melatonin: A Novel Indolamine in Oral Health and Disease

Contact Info

Product

Resources

About